NCT00002234View on ClinicalTrials.gov

Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Efavirenz

DRUG

Adefovir dipivoxil

DRUG

Lamivudine

DRUG

Didanosine

Trial Locations (5)

23666

Hampton Roads Med Specialists, Hampton

30308

AIDS Research Consortium of Atlanta, Atlanta

80262

Univ of Colorado / Health Science Ctr, Denver

90211

Pacific Oaks Med Group, Beverly Hills

02908

Brown Univ School of Medicine, Providence

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Glaxo Wellcome

INDUSTRY

collaborator

Dupont Applied Biosciences

INDUSTRY

lead

Gilead Sciences

INDUSTRY

NCT00002234 - Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients | Biotech Hunter | Biotech Hunter